Top

Clinical Orthopaedics and Related Research®

Published in:

01-12-2009 | Symposium: Tribute to Dr. Marshall Urist: Musculoskeletal Growth Factors

Successful Spinal Fusion by E. coli-derived BMP-2-adsorbed Porous β-TCP Granules: A Pilot Study

Authors: Sho Dohzono, MD, Yuuki Imai, MD, PhD, Hiroaki Nakamura, MD, PhD, Shigeyuki Wakitani, MD, PhD, Kunio Takaoka, MD, PhD

Published in: Clinical Orthopaedics and Related Research® | Issue 12/2009

Abstract

Bone morphogenetic proteins (BMPs) were originally identified as osteoinductive proteins. With cloning of BMP genes, studies of BMPs and their clinical application have advanced. However, with increasing clinical applications, drug delivery systems and production costs have become more important issues. To address these issues, we asked whether E. coli-derived rhBMP-2 (E-BMP-2)-adsorbed porous β-TCP granules could achieve posterolateral lumbar fusion in a rabbit model similar to autogenous bone grafts. Lumbar spinal fusion masses were evaluated by 3-D computed tomography, mechanical testing, and histological analyses 8 weeks after surgery. By these measures E-BMP-2-adsorbed β-TCP granules achieved lumbar spinal fusion in dose-dependent fashion in a rabbit model as well as autogenous bone graft. Our preliminary findings suggest E-BMP-2-adsorbed porous β-TCP could be a novel, effective alternative to autogenous bone grafting for generating new bone and promoting regenerative repair of bone, and potentially utilizable in the clinical setting for treating spinal disorders.

Akamaru T, Suh D, Boden SD, Kim HS, Minamide A, Louis-Ugbo J. Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion. Spine. 2003;28:429–434.CrossRefPubMed

Allen RT, Lee YP, Stimson E, Garfin SR. Bone morphogenetic protein-2 (BMP-2) in the treatment of pyogenic vertebral osteomyelitis. Spine. 2007;32:2996–3006.CrossRefPubMed

Arosarena OA, Collins WL. Bone regeneration in the rat mandible with bone morphogenetic protein-2: a comparison of two carriers. Otolaryngol Head Neck Surg. 2005;132:592–597.CrossRefPubMed

Arrington ED, Smith WJ, Chambers HG, Bucknell AL, Davino NA. Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res. 1996;329:300–309.CrossRefPubMed

Boden SD, Kang J, Sandhu H, Heller JG. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine. 2002;27:2662–2673.CrossRefPubMed

Boden SD, Schimandle JH, Hutton WC. An experimental lumbar intertransverse process spinal fusion model. Radiographic, histologic, and biomechanical healing characteristics. Spine. 1995;20:412–420.PubMedCrossRef

David SM, Gruber HE, Meyer RA, Jr., Murakami T, Tabor OB, Howard BA, Wozney JM, Hanley EN, Jr. Lumbar spinal fusion using recombinant human bone morphogenetic protein in the canine. A comparison of three dosages and two carriers. Spine. 1999;24:1973–1979.CrossRefPubMed

Dimar JR, Glassman SD, Burkus KJ, Carreon LY. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine. 2006;31:2534–2539; discussion 2540.CrossRefPubMed

Glassman SD, Dimar JR, 3rd, Burkus K, Hardacker JW, Pryor PW, Boden SD, Carreon LY. The efficacy of rhBMP-2 for posterolateral lumbar fusion in smokers. Spine. 2007;32:1693–1698.CrossRefPubMed

10.

Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, Aro H, Atar D, Bishay M, Borner MG, Chiron P, Choong P, Cinats J, Courtenay B, Feibel R, Geulette B, Gravel C, Haas N, Raschke M, Hammacher E, van der Velde D, Hardy P, Holt M, Josten C, Ketterl RL, Lindeque B, Lob G, Mathevon H, McCoy G, Marsh D, Miller R, Munting E, Oevre S, Nordsletten L, Patel A, Pohl A, Rennie W, Reynders P, Rommens PM, Rondia J, Rossouw WC, Daneel PJ, Ruff S, Ruter A, Santavirta S, Schildhauer TA, Gekle C, Schnettler R, Segal D, Seiler H, Snowdowne RB, Stapert J, Taglang G, Verdonk R, Vogels L, Weckbach A, Wentzensen A, Wisniewski T. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am. 2002;84:2123–2134.CrossRefPubMed

11.

Grauer JN, Patel TC, Erulkar JS, Troiano NW, Panjabi MM, Friedlaender GE. 2000 Young Investigator Research Award winner. Evaluation of OP-1 as a graft substitute for intertransverse process lumbar fusion. Spine. 2001;26:127–133.CrossRefPubMed

12.

Hoshino M, Namikawa T, Kato M, Terai H, Taguchi S, Takaoka K. Repair of bone defects in revision hip arthroplasty by implantation of a new bone-inducing material comprised of recombinant human BMP-2, Beta-TCP powder, and a biodegradable polymer: an experimental study in dogs. J Orthop Res. 2007;25:1042–1051.CrossRefPubMed

13.

Hsu WK, Wang JC. The use of bone morphogenetic protein in spine fusion. Spine J. 2008;8:419–425.CrossRefPubMed

14.

Itoh H, Ebara S, Kamimura M, Tateiwa Y, Kinoshita T, Yuzawa Y, Takaoka K. Experimental spinal fusion with use of recombinant human bone morphogenetic protein 2. Spine. 1999;24:1402–1405.CrossRefPubMed

15.

Johnsson R, Stromqvist B, Aspenberg P. Randomized radiostereometric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion: 2002 Volvo Award in clinical studies. Spine. 2002;27:2654–2661.CrossRefPubMed

16.

Joseph V, Rampersaud YR. Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis. Spine. 2007;32:2885–2890.CrossRefPubMed

17.

Konishi S, Nakamura H, Seki M, Nagayama R, Yamano Y. Hydroxyapatite granule graft combined with recombinant human bone morphogenic protein-2 for solid lumbar fusion. J Spinal Disord Tech. 2002;15:237–244.PubMed

18.

Kubler NR, Reuther JF, Faller G, Kirchner T, Ruppert R, Sebald W. Inductive properties of recombinant human BMP-2 produced in a bacterial expression system. Int J Oral Maxillofac Surg. 1998;27:305–309.CrossRefPubMed

19.

Kurz LT, Garfin SR, Booth RE, Jr. Harvesting autogenous iliac bone grafts. A review of complications and techniques. Spine. 1989;14:1324–1331.CrossRefPubMed

20.

Lewandrowski KU, Nanson C, Calderon R. Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphogenetic protein 2: a report of five cases. Spine J. 2007;7:609–614.CrossRefPubMed

21.

Martin GJ, Jr., Boden SD, Marone MA, Marone MA, Moskovitz PA. Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. J Spinal Disord. 1999;12:179–186.PubMed

22.

Minamide A, Kawakami M, Hashizume H, Sakata R, Tamaki T. Evaluation of carriers of bone morphogenetic protein for spinal fusion. Spine. 2001;26:933–939.CrossRefPubMed

23.

Minamide A, Kawakami M, Hashizume H, Sakata R, Yoshida M, Tamaki T. Experimental study of carriers of bone morphogenetic protein used for spinal fusion. J Orthop Sci. 2004;9:142–151.CrossRefPubMed

24.

Nakagawa K, Imai Y, Ohta Y, Takaoka K. Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation. Bone. 2007;41:543–548.CrossRefPubMed

25.

Namikawa T, Terai H, Hoshino M, Kato M, Toyoda H, Yano K, Nakamura H, Takaoka K. Enhancing effects of a prostaglandin EP4 receptor agonist on recombinant human bone morphogenetic protein-2 mediated spine fusion in a rabbit model. Spine. 2007;32:2294–2299.CrossRefPubMed

26.

Namikawa T, Terai H, Suzuki E, Hoshino M, Toyoda H, Nakamura H, Miyamoto S, Takahashi N, Ninomiya T, Takaoka K. Experimental spinal fusion with recombinant human bone morphogenetic protein-2 delivered by a synthetic polymer and beta-tricalcium phosphate in a rabbit model. Spine. 2005;30:1717–1722.CrossRefPubMed

27.

Ohta Y, Nakagawa K, Imai Y, Katagiri T, Koike T, Takaoka K. Cyclic AMP enhances Smad-mediated BMP signaling through PKA-CREB pathway. J Bone Miner Metab. 2008;26:478–484.PubMed

28.

Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115:3318–3325.CrossRefPubMed

29.

Ruppert R, Hoffmann E, Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem. 1996;237:295–302.CrossRefPubMed

30.

Saito N, Okada T, Horiuchi H, Murakami N, Takahashi J, Nawata M, Ota H, Nozaki K, Takaoka K. A biodegradable polymer as a cytokine delivery system for inducing bone formation. Nat Biotechnol. 2001;19:332–335.CrossRefPubMed

31.

Sandhu HS, Kanim LE, Kabo JM, Toth JM, Zeegen EN, Liu D, Delamarter RB, Dawson EG. Effective doses of recombinant human bone morphogenetic protein-2 in experimental spinal fusion. Spine. 1996;21:2115–2122.CrossRefPubMed

32.

Santoni BG, Pluhar GE, Motta T, Wheeler DL. Hollow calcium phosphate microcarriers for bone regeneration: in vitro osteoproduction and ex vivo mechanical assessment. Biomed Mater Eng. 2007;17:277–289.PubMed

33.

Sasaoka R, Terai H, Toyoda H, Imai Y, Sugama R, Takaoka K. A prostanoid receptor EP4 agonist enhances ectopic bone formation induced by recombinant human bone morphogenetic protein-2. Biochem Biophys Res Commun. 2004;318:704–709.CrossRefPubMed

34.

Schimandle JH, Boden SD, Hutton WC. Experimental spinal fusion with recombinant human bone morphogenetic protein-2. Spine. 1995;20:1326–1337.PubMed

35.

Seeherman HJ, Bouxsein M, Kim H, Li R, Li XJ, Aiolova M, Wozney JM. Recombinant human bone morphogenetic protein-2 delivered in an injectable calcium phosphate paste accelerates osteotomy-site healing in a nonhuman primate model. J Bone Joint Surg Am. 2004;86:1961–1972.PubMed

36.

Taguchi S, Namikawa T, Ieguchi M, Takaoka K. Reconstruction of bone defects using rhBMP-2-coated devitalized bone. Clin Orthop Relat Res. 2007;461:162–169.PubMed

37.

Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7:292–304.CrossRefPubMed

38.

Toyoda H, Terai H, Sasaoka R, Oda K, Takaoka K. Augmentation of bone morphogenetic protein-induced bone mass by local delivery of a prostaglandin E EP4 receptor agonist. Bone. 2005;37:555–562.CrossRefPubMed

39.

Urist MR. Bone: formation by autoinduction. Science. 1965;150:893–899.CrossRefPubMed

40.

Weigel U, Meyer M, Sebald W. Mutant proteins of human interleukin 2. Renaturation yield, proliferative activity and receptor binding. Eur J Biochem. 1989;180:295–300.CrossRefPubMed

41.

Wong DA, Kumar A, Jatana S, Ghiselli G, Wong K. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J. 2007;8:1011–1018.CrossRefPubMed

42.

Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA. Novel regulators of bone formation: molecular clones and activities. Science. 1988;242:1528–1534.CrossRefPubMed

43.

Wu CH, Hara K, Ozawa H. Enhanced osteoinduction by intramuscular grafting of BMP-beta-TCP compound pellets into murine models. Arch Histol Cytol. 1992;55:97–112.CrossRefPubMed

44.

Yamamoto Y, Udagawa N, Matsuura S, Nakamichi Y, Horiuchi H, Hosoya A, Nakamura M, Ozawa H, Takaoka K, Penninger JM, Noguchi T, Takahashi N. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand. Endocrinology. 2006;147:3366–3374.CrossRefPubMed

45.

Yano K, Hoshino M, Ohta Y, Manaka T, Naka Y, Imai Y, Sebald W, Takaoka K. Osteoinductive capacity and heat stability of recombinant human bone morphogenetic protein-2 produced by Escherichia coli and dimerized by biochemical processing. J Bone Miner Metab. 2009;27:355–363.CrossRefPubMed

46.

Zaidi M. Skeletal remodeling in health and disease. Nat Med. 2007;13:791–801.CrossRefPubMed

Title: Successful Spinal Fusion by E. coli-derived BMP-2-adsorbed Porous β-TCP Granules: A Pilot Study
Authors: Sho Dohzono, MD
Yuuki Imai, MD, PhD
Hiroaki Nakamura, MD, PhD
Shigeyuki Wakitani, MD, PhD
Kunio Takaoka, MD, PhD
Publication date: 01-12-2009
Publisher: Springer-Verlag
Published in: Clinical Orthopaedics and Related Research® / Issue 12/2009
Print ISSN: 0009-921X
Electronic ISSN: 1528-1132
DOI: https://doi.org/10.1007/s11999-009-0960-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Successful Spinal Fusion by E. coli-derived BMP-2-adsorbed Porous β-TCP Granules: A Pilot Study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2009

Correlation of Computed Tomography with Histology in the Assessment of Periprosthetic Defect Healing

The Classic: A Morphogenetic Matrix for Differentiation of Cartilage in Tissue Culture

Journal Scan: Spine

The Classic: Bone Morphogenetic Protein

OP-1 Augments Glucocorticoid-inhibited Fracture Healing in a Rat Fracture Model

Distraction Osteogenesis Enhances Remodeling of Remote Bones of the Skeleton: A Pilot Study